Egalet Corporation, an American specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

According to the law firm press release, the complaint alleges that, among other allegations, throughout the Class Period, Egalet made materially false and/or misleading statements concerning its lead product, ARYMO ER and the likelihood the product would receive oral abuse-deterrent labeling.

On May 1, 2017, the Court appointed Lead Plaintiffs and Counsel. Lead Plaintiffs filed a consolidated Complaint on July 3, 2017. Defendants filed a Motion to Dismiss the consolidated Complaint on September 1. On February 20, 2018, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiffs were given leave to file an amended Complaint. On August 2, the Court issued an Order granting Defendants' Motion to Dismiss with prejudice. On August 31, Lead Plaintiffs filed a Notice appealing the Court's decision. The Court of Appeals affirmed the District Court's judgment on May 22, 2020.